Acne: Effect of hormones on pathogenesis and management

American Journal of Clinical Dermatology

Volumn 3, Issue 8, 2002, Pages 571-578

  Shaw, James C ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; CORTICOSTEROID; CYPROTERONE ACETATE; DESOGESTREL; DEXAMETHASONE; DIANE; DIANE NOVA; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; FINASTERIDE; FLUTAMIDE; GESTAGEN; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT; PREDNISONE; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ACNE; ANDROGEN METABOLISM; BREAST CARCINOMA; BREAST HYPERTROPHY; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; DRUG EFFICACY; DRUG MECHANISM; FETOTOXICITY; HEADACHE; HEART INFARCTION; HORMONAL THERAPY; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERKALEMIA; LETHARGY; LIVER TOXICITY; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEBACEOUS GLAND; STROKE; THROMBOEMBOLISM;

EID: 0036035706     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200203080-00007     Document Type: Review

References (61)

1. Deplewski D, Rosenfield RL. Role of hormones in pilosebaceous unit development. Endocr Rev 2000 Aug; 21: 363-92
2. Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol 1995 Aug; 33: 247-53
3. Webster GF. Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology 1998; 196: 80-1
4. Hamilton JB. Male hormone substance: A prime factor in acne. J Clin Endocrinol Metab 1941; 1: 570-92
5. Pochi PE, Strauss JS, Mescon H. Sebum secretion and urinary fractional 17-ketosteroid and total 17-hydoxycorticoid excretion in male castrates. J Invest Dermatol 1962; 39: 475-83
6. Lookingbill DP, Horton R, Demers LM, et al. Tissue production of androgens in women with acne. J Am Acad Dermatol 1985; 12: 481-7
7. Thiboutot D, Gilliland K, Light J, et al. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 1999; 135: 1041-5
8. Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: Results of a five-year longitudinal study. J Pediatr 1997; 130: 30-9
9. Vexiau P, Huson C, Chivot M, et al. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol 1990; 94: 279-83
10. Slayden SM, Moran C, Sams Jr WM, et al. Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001 May; 75 (5): 889-92
11. Cibula D, Hill M, Vohradnikova O, et al. The role of androgens in determining acne severity in adult women. Br J Dermatol 2000; 143: 399-404
12. Merrill BJ, Gat U, SasGupta R, et al. Tcf3 and Lef1 regulate lineage differentiation of multipotent stem cells in skin. Genes Dev 2001; 15: 1688-705
13. Deplewski D, Rosenfield RL. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology 1999; 140: 4089-94
14. Rosenfield RL, Deplewski D, Kentsis A, et al. Mechanisms of androgen induction of sebocyte differentiation. Dermatology 1998; 196: 43-6
15. Choudhry R, Hodgins MB, Vandr Kwast TH, et al. Localization of androgen receptors in human skin by immunohistochemistry: Implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133: 467-75
16. Liang T, Hoyer S, Yu R, et al. Immunocytochemical localization of androgen receptors in human skin using monoclonal antibodies against the androgen receptor. J Invest Dermatol 1993; 100: 663-6
17. Imperato-McGinley J, Gautier T, Cai L, et al. The androgen control of sebum production: Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993; 76: 524-8
18. Zouboulis CC, Xia L, Akamatsu H, et al. The human sebocyte culture model provides new insights into development and management of seborrhea and acne. Dermatology 1998; 196: 21-31
19. Thiboutot D, Bayne E, Thorne J, et al. Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin. Arch Dermatol 2000 Sep; 136: 1125-9
20. Thiboutot D, Harris G, Iles V, et al. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 1995 Aug; 105: 209-14
21. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: A review of clinical features. Br J Dermatol 1997; 136 (1): 66-70
22. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: A retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol 2000; 43 (3): 498-502
23. Shaw JC. Persistent acne in adult women. Arch Dermatol 2001; 137: 1252-3
24. Petitti DB, Sidney S, Bernstein A, et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996; 335: 8-15
25. Lemay A, Dewailly SD, Grenier R, et al. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,1-norgestrel. J Clin Endocrinol Metab 1990; 71: 8-14
26. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, et al. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate. Int J Fertil 1996; 41: 423-9
27. Dieben TO, Vromans L, Theeuwes A, et al. The effects of CTR-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994; 50: 373-82
28. Janaud A, Rouffy J, Upmalis D, et al. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand 1992; 71: 33-8
29. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997; 37: 746-54
30. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet Gynecol 1997; 89: 615-22
31. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5 Suppl. 3: 25-33
32. Fuhrmann U. Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243-51
33. Shaw JC. Hormonal therapy in dermatology. Dermatol Clin 2001; 19: 169-78
34. Mant J, Painter R, Vessey M. Risk of myocardial infarction, angina and stroke in users of oral contraceptives: An updated analysis of a cohort study. Br J Obstet Gynaecol 1998; 105: 890-6
35. Ober KP, Hennessy JF. Spironolactone therapy for hirsutism in a hyperandrogenic woman. Ann Intern Med 1978; 89: 643-4
36. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol 1984; 111: 124-5
37. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia [letter]. Br J Dermatol 1985; 112: 124-5
38. Hatwal A, Bhatt RP, Agrawal JK, et al. Spironolactone and cimetidine in treatment of acne. Acta Derm Venereol Suppl (Stockh) 1988; 68: 84-7
39. Muhlemann MF, Carter GD, Cream JJ, et al. Oral spironolactone: An effective treatment for acne vulgaris in women. Br J Dermatol 1986; 115: 227-32
40. Shaw JC. Spironolactone in dermatologic therapy. J Am Acad Dermatol 1991; 24: 236-43
41. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol 1988; 118: 687-91
42. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23: 462-9
43. Wang HS, Wang TH, Soong YK. Low dose flutamide in the treatment of acne vulgaris in women with or without oligomenorrhea or amenorrhea. Changgeng Yi Xue Za Zhi 1999; 22: 423-32
44. Cusan L, Dupont A, Gomez JL, et al. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil Steril 1994; 61: 281-7
45. Giordano N, Nardi P, Santacroce C. Acute hepatitis induced by cyproterone acetate. Ann Pharmcother 2001; 35: 1053-5
46. Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223-30
47. Roberts JL, Fiedler V, Imperato-McGinley J, et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41: 555-63
48. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia: Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998; 39: 578-89
49. Erenus M, Yucelten D, Durmusoglu F, et al. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 1997; 68: 1000-3
50. Wong IL, Morris RS, Chang L, et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80: 233-8
51. Moghetti P, Tosi F, Tosti A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: A randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85: 89-94
52. Castello R, Tosi F, Perrone F, et al. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: Clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996; 66: 734-40
53. Erel CT, Senturk LM, Oral I, et al. Results of the ACTH stimulation test in hirsute women. J Reprod Med 1999; 44: 247-52
54. Ostlere LS, Rumsby G, Holownia P, et al. Carrier status for steroid 21-hydroxylase deficiency is only one factor in the variable phenotype of acne. Clin Endocrinol 1998; 48: 209-15
55. Moran C, Azziz R, Carmina E, et al. 21-Hydrozylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: A multicenter study. Am J Obstet Gynecol 2000; 183: 1468-74
56. Ibanez L, Bonnin MR, Zampolli M, et al. Usefulness of an ACTH test in the diagnosis of nonclassical 21-hydroxylase deficiency among children presenting with premature pubarche. Horm Res 1995; 44: 51-6
57. Placzek M, Degitz K, Schmidt H, et al. Acne fulminans in late-onset congenital adrenal hyperplasia. Lancet 1999; 354: 739-40
58. Rittmaster RS, Givner ML. Effect of daily and alternate day low dose prednisone on serum cortisol and adrenal androgens in hirsute women. J Clin Endocrinol Metab 1988; 67: 400
59. Waggoner W, Boots LR, Azziz R. Total testosterone and DHEAS levels as predictors of androgen-secreting neoplasms: A populational study. Gynecol Endocrinol 1999; 13: 394-400
60. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 2108-16
61. Ibanez L, Valls C, Potau N, et al. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85 (10): 3526-30